When Subcutaneous Sumatriptan or High-Flow Oxygen Fails in Chronic Cluster Headache with Daily Attacks

In the subset of patients with chronic cluster headache whose attacks occur daily — and who do not achieve adequate pain relief within 15 minutes on standard first-line acute treatment — a structured next-line approach is indicated.

Clinical Scenario

Chronic cluster headache (ICHD-3 3.1.2) is the less common presentation, accounting for fewer than 20% of cluster headaches. Attacks occur on a daily basis; any symptom-free periods last less than 3 months, sustained over at least 1 year.

First-Line Failure Condition

The first-line acute regimen — subcutaneous sumatriptan or inhalation of 100% high-flow oxygen via nonrebreather mask — targets the patient being pain-free or having only mild pain within 15 minutes. When this pain-relief goal is not reached at 15 minutes, escalation to a next-line protocol is warranted.

Next-Line Approach — Partial Overview

The next-line protocol uses intranasal delivery as the central route of administration, with headache relief at 30 minutes as the target endpoint. Which agents are used, in what order, and under what conditions is defined in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ene.15956

In patients suffering from the less common chronic presentation (<20% of cluster headaches, ICHD-3 3.1.2), attacks often occur on a daily basis; if symptom-free periods are experienced, these last <3 months, for at least 1 year.

An alternative would be zolmitriptan (5 mg) or sumatriptan (20 mg) nasal spray, with the disadvantage of a slower onset than with injected sumatriptan.

Weak recommendations based on consensus further include DHE nasal spray and lidocaine.

Nasal instillation into the ipsilateral nostril of 1 mL 4%-10% lidocaine solution with the patient positioned reclining 45 and 30-40 rotation toward the symptomatic side has been recommended for the reduction of acute symptoms.

Headache relief at 30 min was observed in 63% of patients treated with 10 mg of zolmitriptan (application into the contralateral nostril is recommended) compared with 48% treated with 5 mg of zolmitriptan and 30% treated with placebo.

View source ↗